The Health Resources and Services Administration’s proposed rule that would establish an administrative dispute resolution process for the 340B Drug Pricing Program “is an important first step for 340B hospitals and clinics that have been overcharged for drugs purchased through the program,” but there are several areas in which the rule could be amended, AHA said today. Specifically, the AHA urged HRSA to develop a “fast-track process” to provide 340B hospitals and other covered entities access to 340B drug ceiling prices, which “would help ensure a level-playing field in the dispute resolution process,” AHA Executive Vice President Tom Nickels said in a comment letter on the proposed rule. Among other proposals, AHA also commented on the ADR panel composition and decisions; information requests; and claims initiation and consolidation.

Related News Articles

We’re 11 days into 2019 … we’ve returned to a divided government …and the partial government shutdown continues.
Accountable care organizations interested in participating in the redesigned Medicare Shared Savings Program beginning July 1 must submit their notices of…
Medicare Part B suppliers may deliver the initial immunosuppressive drugs prescribed to a beneficiary after a transplant procedure to an address other than…
Hospitals participating in the first two years of the Comprehensive Care for Joint Replacement model reduced Medicare spending for hip- and knee- replacement…
The AHA Rural Health Care Leadership Conference – one of AHA’s flagship events – will be held Feb. 3-6 in Phoenix. AHA Executive Vice President Maryjane Wurth…
Medicare and Medicaid underpaid U.S. hospitals by $76.8 billion in 2017, according to the latest data from the AHA's Annual Survey of Hospitals.